Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MTATP6P11 is one of several pseudogenes related to the MT-ATP6 gene, which encodes a subunit (subunit a) of the mitochondrial ATP synthase (Complex V, responsible for ATP generation via oxidative phosphorylation) in its functional form[1][4]. As a pseudogene, MTATP6P11 does not encode a protein and is not believed to produce any functional RNA or protein products. There is no current evidence linking MTATP6P11 to any biological functions, disease states, or therapeutic targeting[2][4]. It is found in genomic databases as a nonfunctional genomic element, and is not listed in clinical, disease association, or drug target panels. The functional MT-ATP6 gene (not the pseudogene) is involved in mitochondrial ATP production and is associated with rare mitochondrial diseases when mutated, such as Leigh syndrome[1][7]. MTATP6P11, as a pseudogene, is unrelated to these disorders and does not share their functional or clinical significance. There are no known biomarkers, safety concerns, disease associations, or drugs associated with this pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded ATP synthase 6 pseudogene 11 (MTATP6P11).